No Picture
News

With Approximately 45% of Eosinophilic Esophagitis Patients Going Undiagnosed, the Growth Opportunity for Sanofi/Regeneron’s Dupixent and Future Advanced Therapies Could Be Significant, According to Spherix

Surveyed US gastroenterologists and allergists agree a high unmet need remains, though treatment approach differs between groups EXTON, Pa., Dec. 5, 2022 /PRNewswire/ — Sanofi/Regeneron significantly changed the EoE treatment landscape last May when the […]